Provided by Tiger Trade Technology Pte. Ltd.

Tonix Pharmaceuticals

12.77
-1.2300-8.79%
Post-market: 12.900.1300+1.02%19:59 EDT
Volume:622.01K
Turnover:8.19M
Market Cap:203.56M
PE:-0.91
High:14.01
Open:14.00
Low:12.75
Close:14.00
52wk High:69.97
52wk Low:11.60
Shares:15.94M
Float Shares:13.40M
Volume Ratio:1.42
T/O Rate:4.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0954
EPS(LYR):-14.5713
ROE:-72.33%
ROA:-41.92%
PB:0.90
PE(LYR):-0.88

Loading ...

Tonix Pharmaceuticals posts TNX-4800 Lyme disease prevention presentation

Reuters
·
May 18

Tonix publishes TNX-1500 xenotransplantation workshop presentation

Reuters
·
May 18

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Tonix Pharma (TNXP) and Regeneron (REGN)

TIPRANKS
·
May 18

Tonix publishes investor deck highlighting TONMYA fibromyalgia launch strategy

Reuters
·
May 15

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

GlobeNewswire
·
May 14

Tonix Pharmaceuticals to present at RBC Capital Markets Global Healthcare Conference

Reuters
·
May 13

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

GlobeNewswire
·
May 13

Analysts’ Top Healthcare Picks: Dexcom (DXCM), Tonix Pharma (TNXP)

TIPRANKS
·
May 12

Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year

TIPRANKS
·
May 12

Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate

Benzinga
·
May 12

Tonix Q1 FY26 net loss widens to $40.2 million; net product revenue rises to $6.9 million

Reuters
·
May 12

Tonix Pharmaceuticals: Expect to Begin Phase 2 Study of Tonmya for Treatment of Major Depressive Disorder (Mdd) Mid-Year

THOMSON REUTERS
·
May 12

Tonix Pharmaceuticals: to Initiate Adaptive Phase 2 Field Study for Prevention of Lyme Disease in U.S. in H1 2027 for Tnx-4800, Pending FDA Agreement

THOMSON REUTERS
·
May 12

Tonix Pharmaceuticals Q1 EPS USD -2.93

THOMSON REUTERS
·
May 12

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

GlobeNewswire
·
May 12

Alliance Global Partners Keeps Their Buy Rating on Tonix Pharma (TNXP)

TIPRANKS
·
May 11

EXE, IP, ESPR, CMPS, TNXP Trending With Analysts

TIPRANKS
·
May 09

Tonix Pharmaceuticals Holding Corp expected to post a loss of $2.43 a share - Earnings Preview

Reuters
·
May 08

Tonix Pharmaceuticals shareholders approve 2026 stock incentive plan at annual meeting

Reuters
·
May 08